ZGZhifang Guo

Zhifang Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Zhifang Guo has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Huikun Zhang

    Department of Tumor Cell Biology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Tianjin, China

    1 shared publication
  • Jiaqi Jin

    Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China

    1 shared publication
  • Lang Chen

    Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China

    1 shared publication
  • Manzhi Gao

    Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China

    1 shared publication
  • Shaolu Zhang

    Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China

    1 shared publication
  • Siqing Sun

    Laboratory of Cancer Cell Biology, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China

    1 shared publication

Latest Publications

  • Open Access

    Acetylation-driven non-canonical transcriptional repressor ITSN1-S targets RASGRF1-GPX4 axis to induce breast cancer ferroptosis and anti-tumor immune remodeling

    by Huikun Zhang, Siqing Sun, Yawen Zhao, Manzhi Gao, Lang Chen, Xiaoli Liu, Zhifang Guo, Jiaqi Jin, Shaolu Zhang, Yongjie Ma

    Breast cancer remains the most prevalent malignancy among women worldwide, yet robust molecular biomarkers are still lacking to advance precision oncology. Integrative analyses of our single-cell RNA sequencing (scRNA-seq) and mRNA microarray datasets identified endocytic protein, the short isoform of intersectin 1 (ITSN1-S), as a previously uncharacterized tumor suppressor, with its nuclear accumulation positively correlating with clinical prognosis in breast cancer. Mechanistically, CREB-binding protein (CBP)‑mediated acetylation facilitated nuclear translocation of ITSN1-S, enabling it to function as a non-canonical transcriptional repressor. Via directly binding to A/GCACACA core motif within RASGRF1 promoter, nuclear ITSN1-S transcriptionally repressed RASGRF1 . Functionally, this transcriptional repression inhibited breast cancer malignant progression and downregulated GPX4, thereby sensitizing breast cancer cells to cisplatin-induced ferroptosis. Further functional assays demonstrated that ITSN1-S-RASGRF1 axis-triggered tumor ferroptosis remodeled tumor immune microenvironment by driving tumor-associated macrophage (TAM) polarization towards anti-tumor M1 phenotype both in vitro and in vivo. Consistently, combined nuclear ITSN1-S and RASGRF1 expression status served as an independent prognostic factor for breast cancer patients. Collectively, this study advanced mechanistic insights into non-canonical transcriptional regulation driven by post-translationally modified endocytic proteins and offered promising prognostic biomarkers and druggable targets to reverse cisplatin resistance for breast cancer treatment.